The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial‐onset seizures: A randomized, double‐blind, placebo‐controlled, parallel‐group phase III study
Abstract
Summary: Purpose: To study the efficacy and safety of eslicarbazepine acetate (ESL) as adjunctive therapy for refractory partial seizures in adults with ≥4 partial‐onset seizures (simple or complex, with or without secondary generalization) per 4 weeks despite treatment with 1–2 antiepileptic drugs (AEDs). Methods: This multicenter, parallel‐group study had an 8‐week, single‐blind, placebo baseline phase, after which patients were randomized to placebo (n = 102) or once‐daily ESL 400 mg (n = 100), 800 mg (n = 98), or 1,200 mg (n = 102) in the double‐blind treatment phase. ESL starting dose was 400 mg; thereafter, ESL was titrated at weekly 400‐mg steps to the full maintenance dose (12 weeks). Results: Seizure frequency adjusted per 4 weeks over the maintenance period (primary endpoint) was significantly lower than placebo in the ESL 1,200‐mg (p = 0.0003) and 800‐mg (p = 0.0028) groups [analysis of covariance (ANCOVA) of log‐transformed seizure frequency]. Responder rate was 20% (placebo), 23% (400 mg), 34% (800 mg), and 43% (1,200 mg). Median relative reduction in seizure frequency was 16% (placebo), 26% (400 mg), 36% (800 mg), and 45% (1,200 mg). The most frequent concomitant AEDs were carbamazepine (56–62% of patients), lamotrigine (25–27%), and valproic acid (22–28%). Similar efficacy results were obtained in patients administered ESL with or without carbamazepine as concomitant AED. Discontinuation rates caused by adverse events (AEs) were 3.9% (placebo), 4% (400 mg), 8.2% (800 mg), and 19.6% (1,200 mg). AEs in >10% of any group were dizziness, headache, and diplopia. Most AEs were mild or moderate. Discussion: ESL, 800 and 1,200 mg once‐daily, was well tolerated and more effective than placebo in patients who were refractory to treatment with one or two concomitant AEDs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Early Identification of Refractory Epilepsy
Kwan, P., & Brodie, M. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002033420503 · Cited by 5,204
Epilepsy: A Comprehensive Textbook
(2008) · JAMA · doi:10.1001/jama.300.4.443-a · Cited by 2,341
Mattson, R. H., Cramer, J. A., & Collins, J. F. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209103271104 · Cited by 683
Molecular and cellular mechanisms of pharmacoresistance in epilepsy
Remy, S., & Beck, H. (2006) · Brain · doi:10.1093/brain/awh682 · Cited by 406
Seizure-Induced Plasticity of h Channels in Entorhinal Cortical Layer III Pyramidal Neurons
Shah, M. M., Anderson, A. E., Leung, V., Lin, X., & Johnston, D. (2004) · Neuron · doi:10.1016/j.neuron.2004.10.011 · Cited by 288
Topiramate and Psychiatric Adverse Events in Patients with Epilepsy
Mula, M., Trimble, M. R., Lhatoo, S. D., & Sander, J. W. A. S. (2003) · Epilepsia · doi:10.1046/j.1528-1157.2003.05402.x · Cited by 254
Oxcarbazepine Placebo‐Controlled, Dose‐Ranging Trial in Refractory Partial Epilepsy
(2000) · Epilepsia · doi:10.1111/j.1499-1654.2000.001597.x · Cited by 225
Bender, R. A., Soleymani, S. V., Brewster, A. L., Nguyen, S. T., Beck, H., Mathern, G. W., & Baram, T. Z. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-17-06826.2003 · Cited by 199
Eslicarbazepine Acetate (BIA 2-093)
Almeida, L., & Soares-da-Silva, P. (2007) · Neurotherapeutics · doi:10.1016/j.nurt.2006.10.005 · Cited by 185
Self-citation
Cited by
Key factors in the discovery and development of new antiepileptic drugs
Bialer, M., & White, H. S. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2997 · Cited by 542
Antiepileptic drug interactions—Principles and clinical implications
I. Johannessen, S., & Johannessen Landmark, C. (2010) · Current Neuropharmacology · doi:10.2174/157015910792246254 · Cited by 343
Ryvlin, P., Cucherat, M., & Rheims, S. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70193-4 · Cited by 338
Grunze, H., Kotlik, E., Costa, R., Nunes, T., Falcão, A., Almeida, L., & Soares-da-Silva, P. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.11.013 · Cited by 22
Self-citation
Metadata
- Authors
- Elger, C., Halász, P., Maia, J., Almeida, L., Soares‐da‐Silva, P., & on behalf of the BIA‐2093‐301 Investigators Study Group
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 2009-03
- Volume
- 50
- Issue
- 3
- Pages
- 454-463
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W1984234523
- Cited by
- 252
- References
- 11
- FWCI
- 12.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial‐onset seizures: A randomized, double‐blind, placebo‐controlled, parallel‐group phase III study. https://app.cochat.ai/papers/10.1111/j.1528-1167.2008.01946.x
- The paper
- Elger, C., Halász, P., Maia, J., Almeida, L., Soares‐da‐Silva, P., & on behalf of the BIA‐2093‐301 Investigators Study Group. (2009). Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial‐onset seizures: A randomized, double‐blind, placebo‐controlled, parallel‐group phase III study. Epilepsia. https://doi.org/10.1111/j.1528-1167.2008.01946.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.